Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,500.00

Eli Lilly and Company (NYSE:LLY) had its price target hoisted by JPMorgan Chase & Co. from $1,400.00 to $1,500.00 in a research report report published on Monday morning, MarketBeat.com reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

LLY has been the subject of several other reports. Sanford C. Bernstein upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a report on Tuesday, July 14th. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Citigroup lifted their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 23rd. Finally, TD Cowen restated a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,311.96.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,161.73 on Monday. The business’s 50-day simple moving average is $1,178.06 and its 200-day simple moving average is $1,087.21. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 52 week low of $763.30 and a 52 week high of $1,292.65. The firm has a market cap of $1.09 trillion, a price-to-earnings ratio of 38.98, a P/E/G ratio of 1.45 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same period in the previous year, the company earned $6.31 EPS. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by company insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in the company. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. bought a new position in Eli Lilly and Company in the fourth quarter worth $30,000. Maseco LLP boosted its stake in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after buying an additional 28 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in Eli Lilly and Company during the fourth quarter worth $39,000. Finally, Aventus Investment Advisors Inc. increased its holdings in Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after buying an additional 27 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Next-generation obesity treatment delivered strong results. Lilly’s experimental EloraTZP combination of eloralintide and tirzepatide produced average weight loss of up to 23.3%, versus 14.8% for Zepbound 15 mg, while also delivering greater A1C reductions. Lilly plans to begin Phase 3 testing in the fourth quarter of 2026. Experimental Lilly combination drug tops Zepbound in weight-loss trial
• Positive Sentiment: Retatrutide showed substantial weight-loss potential. In a late-stage diabetes trial, the investigational triple-agonist treatment helped patients lose nearly 21% of body weight, reinforcing Lilly’s prospects beyond its current Zepbound franchise. Lilly’s experimental drug cuts weight by 21% in diabetes trial
• Positive Sentiment: Foundayo and Ebglyss added pipeline support. Lilly said oral GLP-1 Foundayo met cardiovascular safety requirements while maintaining A1C and weight benefits, and Ebglyss delivered significant skin-clearance, itch and pain improvements in hand-and-foot atopic dermatitis. Foundayo cardiovascular safety study
• Neutral Sentiment: Competitive positioning remains mixed. Lilly’s analyses showed Zepbound and Foundayo outperforming certain Novo Nordisk semaglutide products on weight loss, but Novo reported real-world data suggesting higher-dose Ozempic had lower cardiovascular-event risk than Mounjaro. The comparisons are not direct head-to-head trials, limiting their immediate investment significance. Novo cardiovascular comparison
• Negative Sentiment: Market concerns overshadowed favorable clinical news. Investors remain focused on intense competition, potential pricing pressure, emerging challengers such as Roche, and criticism of Lilly’s direct-to-consumer Mounjaro delivery approach. With Lilly valued at roughly $1.1 trillion and trading at a high earnings multiple, strong results may already be reflected in the share price.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.